Two divisions of Serologicals and Pittsburgh-based biotech Cellumen plan to co-develop and sell a cytotoxicity profiling panel and services for use in pharmaceutical drug discovery, the firms said this week.

For reagent provider Serologicals, the partnership marks the biggest step it has taken to date in the direction of cell-based assays for drug discovery; specifically, it expects the deal to help it gain a foothold in the high-content cellular-assay market, an area in which it has limited experience.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.